Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 

NZ scientists lead world in osteoporosis deal


NZ scientists lead world in osteoporosis deal

Auckland, 15 August 2002: New discoveries by scientists at The University of Auckland have resulted in a substantial trans-Tasman licensing agreement to develop a potential world-first treatment for osteoporosis, Auckland UniServices Limited announced today.

Johanna Stapelberg, Intellectual Property Manager for UniServices, which owns and manages the University’s intellectual property portfolio, said the deal marked a significant achievement for New Zealand university-led research and offered a prospective drug therapy for a bone-thinning disease now reaching epidemic proportions, particularly among women and the elderly.

Success in commercially developing new drugs based on the discoveries could result in very significant royalty payments to the University, as worldwide sales of osteoporosis drugs now exceed US$2.8 billion and are projected to reach US$9.3 billion by 2009.

“To date, other potential treatments have had serious side effects and have focused solely on reducing factors that cause bone loss. By contrast, the compounds developed by the University team not only appear to be free of side effects, but also have the unique potential to both stop bone loss and actively promote bone-cell growth,” Ms Stapelberg said.

Under the agreement, Melbourne-based biotechnology company, Metabolic Pharmaceuticals Ltd, will develop two drugs discovered by a team led by Professor Ian Reid and Associate Professor Jillian Cornish at the University’s Bone Research Group, in association with Professor Garth Cooper at the School of Biological Sciences.


Osteoporosis affects 56 per cent of women and 29 per cent of men aged over 60. The disease results from an imbalance in the normal bone-rebuilding cycle where ageing bone is broken down by special-purpose cells called osteoclasts and replaced with new bone by the action of bone-building cells, or osteoblasts. Due to the effect loss of estrogen has of accelerating bone loss this bone-thinning process may be accentuated in women immediately after menopause.

In New Zealand, osteoporosis causes 15,000 fractures each year, of which around 3,000 are hip fractures. And for elderly people in particular, Professor Reid said, the consequences of losing independence and mobility can be severe.

“Up to 20 per cent of aged osteoporosis patients die after a hip fracture, and 40 per cent can no longer live independently within a year of their injury,” he said.

The Auckland team began this research more than 10 years ago, by investigating why obese people were less likely to lose bone density than others.

Obtaining significant support from the Health Research Council, the scientists identified the hormones amylin and adrenomedullin, which are associated with obesity, and discovered that fragments of these compounds actively promote bone building. Using this knowledge, the team has developed compounds that can both promote this growth while at the same time reducing bone loss.

To date, the Bone Research Group has conducted extensive testing of the two lead compounds, with promising outcomes published in peer-reviewed journals last year.

“To bring something that started as pure research to this point where we are looking at potential treatments for people with osteoporosis has been an exciting achievement for the whole team,” Associate Professor Cornish said. “If successful, these compounds could bring help to an increasingly large proportion of the population who will be affected by osteoporosis.”

Under the agreement, Metabolic will pay UniServices – which has patented the discoveries on behalf of The University – milestone fees and a royalty in return for exclusive worldwide rights. The Auckland team will continue to be involved in the development of the drugs.

More than 200 million people are estimated to suffer osteoporosis, and the disease is forecast to become a major burden on an ageing society.

“The compounds discovered by the Auckland team are the result of several years of highly original research by people who are recognised as international leaders,” said Chris Belyea, Metabolic’s CEO. “These new discoveries have a strong potential to improve the treatment of osteoporosis, and we are delighted to have the opportunity to develop them.”

Auckland UniServices Limited

Auckland UniServices Limited is New Zealand’s leading knowledge and technology transfer company, linking industry to the resources and skills of The University of Auckland.

UniServices is wholly owned by The University of Auckland. It manages the University’s commercial research contracts, owns and commercialises its intellectual property estate, and forms new companies based around the University’s intellectual property.

http://www.uniservices.co.nz


Metabolic

Metabolic Pharmaceuticals Ltd (ASX:MBP) is a biotechnology company based in Melbourne, Australia developing a pipeline of pharmaceutical compounds to provide new drugs for world markets, with active programs in obesity, type II diabetes, iron overload and osteoporosis. Metabolic’s most advanced compound is AOD9604 for obesity. The company recently completed intravenous Phase 2A clinical trials on AOD9604 with promising results, and is proceeding into oral Phase 2A clinical trials shortly. AOD9604 directly affects the metabolism of fat and is an analog of a fragment of the human growth hormone molecule.
Further details on the Osteoporosis Compounds, including published information, will be placed on the Metabolic website.

Contact Information:

Website: www.metabolic.com.au

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 

Commerce Commission: Latest Broadband Report Confirms Improved Performance Of Premium Fibre Plans

The latest report from the Commerce Commission’s Measuring Broadband New Zealand programme shows that the performance of Fibre Max plans has improved substantially. This follows a collaboration between the Commission, its independent testing partner, ... More>>

Air New Zealand: Capital Raise Deferred

Air New Zealand has decided to defer its planned capital raise to later in 2021 allowing more time to assess the impacts of recent developments on the airline’s path to recovery. 'We’ve seen some clearing of COVID-19 clouds recently, with ... More>>

Commerce Commission: Cartel Conduct Now Punishable By Up To 7 Years’ Jail Time

Cartel conduct can now be punished with a term of imprisonment of up to 7 years, after the Commerce (Criminalisation of Cartels) Amendment Act 2019 came into effect today. Cartel conduct includes price fixing, market allocation and bid rigging (see ... More>>

Stats NZ: Auckland Population May Hit 2 Million In Early 2030s

Auckland’s population may rise from about 1.7 million currently to 2 million by early next decade, Stats NZ said today. “Auckland will likely have the highest average annual growth of New Zealand’s 16 regions over the next 30 years, from ... More>>


Stats NZ: March Card Spending Rebounds Despite COVID

There was a lift in retail card spending in March following a fall in the lockdown-disrupted February month, Stats NZ said today. Seasonally adjusted retail card spending rose by $53 million (0.9 percent), compared with February 2021. Visit our website to read ... More>>

PwC: Outcome Of Review Into Air New Zealand Gas Turbines Business

Air New Zealand has received the report into its Gas Turbines business from independent external advisers PwC. Air New Zealand Chairman Dame Therese Walsh says the report identified a range of effective controls in the Gas Turbines revenue contracting ... More>>

LPG Association: Renewable LPG Achieves Emissions Budgets With No Need To Ban New LPG Connections

Renewable LPG can supply New Zealand’s LPG needs and achieve the emissions reductions proposed by the Climate Commission without the need to ban new connections, a new study shows. The investigation, by leading consultancy Worley, was prepared for the ... More>>